Trial site
CONEXA Investigacion Clinica S.A.
Buenos Aires, 1012, ArgentinaNot linked to an institution yet
- 11running trials
- 4closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 41 trial
- Status
- Recruiting5 trials
- Active, not recruiting4 trials
- Completed4 trials
- Enrolling by invitation1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Eli Lilly and Company10 trials
- Bristol-Myers Squibb3 trials
- Takeda2 trials
Running trials
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579· Phase 3· Eli Lilly and Company· Source
Contact: María Scioscia (principal investigator)
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· Phase 3· Eli Lilly and Company· Source
Contact: María Scioscia (principal investigator)
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453· Phase 3· Bristol-Myers Squibb· Source
Contact: Pablo Gonzalez, Site 0149
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Contact: María Scioscia (principal investigator)
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· Phase 3· Bristol-Myers Squibb· Source
Contact: Pablo Javier Gonzalez, Site 0061
Active, not recruiting
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· Phase 3· Takeda· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Enrolling by invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT04772079· Phase 3· Bristol-Myers Squibb· Source
Contact: Pablo Gonzalez, Site 0058
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error